Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ThermoGenesis has received authorization from the FDA to begin marketing its MarrowXpress device for use in a clinical laboratory setting or intraoperatively for preparation of a cell concentrate from bone marrow.
Subscribe to our email newsletter
The company has previously submitted a 510(k) pre-market notification application to the FDA. Upon its review, the FDA determined that the device was exempt from the agency’s pre-market notification requirements and will instead be regulated as laboratory equipment labeled for a specific medical use.
ThermoGenesis’s MarrowXpress (MXP) device is a derivative of the company’s AutoXpress Platform that is used to volume reduce and collect stem cells from umbilical cord blood.
John Chapman, vice president of R&D and scientific affairs, at ThermoGenesis, said: “While the initial marketing application for the MXP will be for bone marrow processing, both at point-of-care and in a laboratory, we will continue our exploration of the use of this technology platform for other sources of adult stem cells including mobilized peripheral blood and adipose tissue stem cell processing.”